AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript

SA Transcripts 161.55K Followers Follow AbCellera Biologics Inc. ( ABCL ) Q2 2026 Earnings Call August 5, 2026 5:00 PM EDT Company Participants Tryn Stimart - Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Brendan Smith - TD Cowen, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good afternoon, and welcome to AbCellera's Q2 2026 Business Update Conference Call. My name is Jonathan, and I will facilitate the audio portion of today's interactive broadcast. At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. You may proceed. Tryn Stimart Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer Thank you. Hello, everyone. Thank you for joining us for AbCellera's Second Quarter 2026 Earnings Call. I'm Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Dr. Carl Hansen, AbCellera's President and CEO; and Andrew Booth, AbCellera's Chief Financial Officer, are speaking on today's call. During this call, we may make statements about our strategic priorities and financial outlook based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those described. Please review the Risk Factors section of our most recent Form 10-K and subsequent 10-Q filings with the SEC for a more detailed discussion of these risks. AbCellera assumes no obligation to update any forward-looking